Brief: Redhill Biopharma's Oral Opaganib Reduces Mortality By 70% Given On Top Of Remdesivir And Corticosteroids In Severe Covid-19

Redhill Biopharma

07/02/2022 16:52

Feb 7 (Reuters) - Redhill Biopharma Ltd  RDHy.F :
    * REDHILL BIOPHARMA'S ORAL OPAGANIB REDUCES MORTALITY BY 70%
GIVEN
ON TOP OF REMDESIVIR AND CORTICOSTEROIDS IN SEVERE COVID-19
    * REDHILL BIOPHARMA LTD - OPAGANIB DATA SUBMISSIONS
INITIATED IN
Q4/21
    * REDHILL BIOPHARMA - FIRST ANALYSIS SHOWED OPAGANIB
SIGNIFICANTLY
REDUCED MORTALITY WHEN GIVEN TO PATIENTS WHO RECEIVED REMDESIVIR
& CORTICOSTEROIDS
    * REDHILL BIOPHARMA LTD - SECOND ANALYSIS FURTHER SHOWED
THAT
OPAGANIB DELIVERED A SIGNIFICANT BENEFIT IN TIME TO RECOVERY
    * REDHILL BIOPHARMA LTD - ADVANCING REGULATORY DISCUSSIONS
IN
MULTIPLE COUNTRIES
    * REDHILL BIOPHARMA LTD - POTENTIAL EMERGENCY AND MARKETING
AUTHORIZATION APPLICATIONS FOR OPAGANIB PLANNED IN H1/2022
    * REDHILL BIOPHARMA LTD - OPAGANIB DATA SUBMISSIONS
INITIATED IN
Q4 2021 IN U.S., EUROPE, UK AND ADDITIONAL COUNTRIES
    * REDHILL BIOPHARMA - INITIAL GUIDANCE ON OPAGANIB
CONFIRMATORY
STUDY, POTENTIAL PATH TO APPROVAL RECEIVED FROM EU'S EMA, U.S.
FDA, UK'S MHRA, OTHERS

Source text for Eikon:  ID:nPn8Bx6H0a 
Further company coverage:  RDHy.F 

 ((Reuters.Briefs@thomsonreuters.com;))